Nawaid Usmani

Dr. Nawaid Usmani


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
Lin YangLin Yang
Lin Yang
AMAndria R. Morielli
Andria R. Morielli
EHEmily Heer
Emily Heer
AKAmy A Kirkham
Amy A Kirkham
WCWinson Cheung
Winson Cheung
OCOralee Courneya
Oralee Courneya
We systematically reviewed and synthesized evidence on the impact of physical activity/exercise on cancer treatment efficacy. We included six preclinical and seven clinical studies. Exercise significantly enhanced the efficacy of chemotherapy and tamoxifen in seven of eight rodent models in either an additive, sensitizing, or synergistic manner. In clinical studies, preliminary evidence indicates that exercise during neoadjuvant, primary, and adjuvant treatment may enhance efficacy of cancer therapies; however, no clinical study was designed for this purpose. Here we discuss the biological mechanisms of exercise-associated enhancement of therapeutic efficacy and propose future research directions to definitively examine the effects of exercise on cancer treatment and patient outcomes.

1 November 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
DDDeepak Dinakaran
Deepak Dinakaran
JSJayeeta Sengupta
Jayeeta Sengupta
DPDesmond Pink
Desmond Pink
ARArun Raturi
Arun Raturi
HCHua Chen
Hua Chen
RMRonald B Moore
Ronald B Moore

11 February 2016 in IEEE Robotics and Automation Letters
Verified
Journal Article
Closed access
BFBita Fallahi
Bita Fallahi
CRCarlos Rossa
Carlos Rossa
RSRon S. Sloboda
Ron S. Sloboda
NUNawaid Usmani
Nawaid Usmani
Mahdi TavakoliMahdi Tavakoli
Mahdi Tavakoli
This letter represents a sliding-based controller for steering beveled-tip needles to stationary locations in soft tissue in a 2-D environment by performing appropriate switches of bevel orientation by 180° axial rotations while the needle is being inserted. Assuming the rotation velocity to be large enough with respect to insertion velocity, the out of plane motions of the needle can be neglected. The proposed controller has a nonmodel-based structure, which is fed by the needle tip deflection error and its derivative obtained from ultrasound images and outputs the switching pattern as the control law. To analyze the stability and convergence of the error, the kinematic unicycle model for beveled-tip needle motion in soft tissue is employed and the constraints on switching parameters are derived. The performance of the controller in the sense of targeting error and number of switches is verified using an experimental setup to insert the needle into gelatin phantom tissue and ex-vivo biological tissue.

2 June 2013 in Journal of Sensors
Verified
Journal Article
Open access
PDF file
TLThomas Lehmann
Thomas Lehmann
Mahdi TavakoliMahdi Tavakoli
Mahdi Tavakoli
NUNawaid Usmani
Nawaid Usmani
RSRonald Sloboda
Ronald Sloboda
A virtual sensor is developed for the online estimation of needle tip deflection during permanent interstitial brachytherapy needle insertion. Permanent interstitial brachytherapy is an effective, minimally invasive, and patient friendly cancer treatment procedure. The deflection of the needles used in the procedure, however, undermines the treatment efficiency and, therefore, needs to be minimized. Any feedback control technique to minimize the needle deflection will require feedback of this quantity, which is not easy to provide. The proposed virtual sensor for needle deflection incorporates a force/torque sensor, mounted at the base of the needle that always remains outside the patient. The measured forces/torques are used by a mathematical model, developed based on mechanical needle properties. The resulting estimation of tip deflection in real time during needle insertion is the main contribution of this paper. The proposed approach solely relies on the measured forces and torques without a need for any other invasive/noninvasive sensing devices. A few mechanical models have been introduced previously regarding the way the forces are composed along the needle during insertion; we will compare our model to those approaches in terms of accuracy. In order to conduct experiments to verify the deflection model, a custom-built, 2-DOF robotic system for needle insertion is developed and discussed. This system is a prototype of an intelligent, hand-held surgical assistant tool that incorporates the virtual sensor proposed in this paper.

1 July 2011 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
NUNawaid Usmani
Nawaid Usmani
RSRon Sloboda
Ron Sloboda
WKWafa Kamal
Wafa Kamal
SGSunita Ghosh
Sunita Ghosh
NPNadeem Pervez
Nadeem Pervez
TMTara Monajemi
Tara Monajemi

4 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Andreia BrandaoAndreia Brandao
Andreia Brandao
PPPaula Paulo
Paula Paulo
SMSofia Maia
Sofia Maia
MPManuela Pinheiro
Manuela Pinheiro
APAna Peixoto
Ana Peixoto
MTManuel R. Teixeira
Manuel R. Teixeira
The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case–control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1–3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families.